carmustine + teniposide

Carmustine + teniposide is a combination of two chemotherapeutic agents used primarily in the treatment of certain malignancies such as primary central nervous system lymphoma and has been studied in recurrent glioblastoma and refractory lymphomas. Carmustine is a nitrosourea alkylating agent that exerts its antitumor effect by alkylating DNA and RNA, leading to cross-linking and inhibition of replication and transcription. It may also carbamoylate proteins to inhibit key enzymatic processes[3][7]. Teniposide is a semisynthetic podophyllotoxin derivative that inhibits topoisomerase II activity, causing dose-dependent single- and double-stranded DNA breaks which prevent cell division during the late S or early G2 phase of the cell cycle[5][6]. The combination has been used in multi-agent regimens for aggressive or refractory cancers but is not widely approved as a fixed commercial product.

Brand names

Gliadel Wafer